ConductScience.org, home

Paper40176396

Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.

Ji D and 11 others. Thorac Cancer, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data. Papers, record 40176396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40176396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.
PubMed
Journal
Thorac Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-05-15
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ji DDanyang
2Lan BBo
3Wang JJiayu
4Ma FFei
5Luo YYang
6Li QQing
7Zhang PPin
8Cai RRuigang
9Li QQiao
10Chen SShanshan
11Xu BBinghehttps://orcid.org/0000-0003-4195-337X
12Fan YYinghttps://orcid.org/0009-0004-7038-8239

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Neoadjuvant TherapyMajor topic
Humans
Female
Middle Aged
Prognosis
Axilla
Adult
Aged
Lymph Nodes
Lymphatic Metastasis
Chemotherapy, Adjuvant

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2021-I2M-1-014CAMS Innovation Fund for Medical SciencesPubMed
2022-I2M-2-002CAMS Innovation Fund for Medical SciencesPubMed
2023-I2M-C&T-B-077CAMS Innovation Fund for Medical SciencesPubMed
CICAMS-MOMP202203Major project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical SciencesPubMed

Source PubMed

Download CSV of grants

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1714108Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.N Engl J Med1978https://conductscience.org/library/papers/714108PubMed
229368152A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.Ann Surg Oncol2018https://conductscience.org/library/papers/29368152PubMed
328075166The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Future Oncol2017https://conductscience.org/library/papers/28075166PubMed
49215816Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol1997https://conductscience.org/library/papers/9215816PubMed
531928404Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.J Clin Oncol2020https://conductscience.org/library/papers/31928404PubMed
633538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
717545614Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.Cancer Res2007https://conductscience.org/library/papers/17545614PubMed
89704717Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol1998https://conductscience.org/library/papers/9704717PubMed
930373556Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.BMC Cancer2018https://conductscience.org/library/papers/30373556PubMed
1018484198Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.Breast Cancer Res Treat2009https://conductscience.org/library/papers/18484198PubMed
1125501357The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.PLoS One2014https://conductscience.org/library/papers/25501357PubMed
1234171619
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study.
Breast2021https://conductscience.org/library/papers/34171619PubMed
1330814109Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.Clin Cancer Res2019https://conductscience.org/library/papers/30814109PubMed
1432046998Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.Clin Cancer Res2020https://conductscience.org/library/papers/32046998PubMed
1528564564Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.N Engl J Med2017https://conductscience.org/library/papers/28564564PubMed
1633232761Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Ann Oncol2021https://conductscience.org/library/papers/33232761PubMed
1725781576Ki67--no evidence for its use in node-positive breast cancer.Nat Rev Clin Oncol2015https://conductscience.org/library/papers/25781576PubMed
1823828499Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.Breast Cancer Res Treat2013https://conductscience.org/library/papers/23828499PubMed
1925332249Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.J Clin Oncol2014https://conductscience.org/library/papers/25332249PubMed
2029758503MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.Breast2018https://conductscience.org/library/papers/29758503PubMed

See all 30 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40176396

GET https://conductscience.org/api/papers/v1/40176396/references?page=2